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Abstract
Background: To evaluate the safety and effectiveness of the Supracor excimer laser algorithm to treat hyperopic
presbyopic patients using laser in-situ keratomileusis (LASIK).
Methods: This is a retrospective case review of patients diagnosed with hyperopia (Sphere ≥ +0.0 D and
presbyopia reading add ≥ 1.0 D) who underwent Supracor excimer laser treatment on at least one eye for
presbyopia correction from year May 2011 to May 2013. Binocular vision was further analyzed after patients were
subdivided into three groups: Group A (n = 22 eyes, 11 patients) had Supracor on both eyes; Group B (n = 18 eyes,
18 patients) had Supracor in one eye and hyperopic LASIK on fellow eye; and Group C (n = 29 eyes, 29 patients)
had Supracor in one eye and no treatment on the fellow eye.
Results: This study evaluated 58 patients wherein 69 eyes underwent Supracor presbyopic LASIK. Preoperatively,
mean manifest refraction spherical equivalent (MRSE) of all eyes that underwent Supracor was +1.37 ± 0.72 D with
mean uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), and uncorrected
near visual acuity (UNVA) of 20/50 (0.35 logMAR), 20/50 (0.35 logMAR), and J9 (0.61 logMAR), respectively. At 6 months
postoperatively, mean MRSE was −0.43 ± 0.59 D with mean UDVA, UIVA and UNVA of 20/25 (0.13 logMAR), 20/20
(0.01 logMAR), and J1 (0.05 logMAR), respectively. Loss of two lines of best-corrected distance visual acuity (BCDVA) was
seen in 6% of eyes. Mean corneal steepening of 1.0 D at the 3 mm zone and 0.7 D in the 5 mm zone was observed.
Mean vertical coma increased from −0.02 to +0.10 while mean 4th order spherical aberration became more negative
from 0.20 to −0.14. Mean binocular UDVA, UIVA, and UNVA are 20/20, 20/20 and J1, respectively, in all treatment
groups at the 6 month postoperative follow-up. No significant differences in binocular UDVA (p≥ 0.36), UIVA (p≥ 0.19)
and UNVA (p≥ 0.56) among groups were seen.
Conclusions: Supracor excimer laser algorithm is safe and effective for the treatment of presbyopia in hyperopes.
Monolateral and bilateral Supracor treatments yielded similarly good binocular vision outcomes.
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Background
Presbyopia is a condition wherein the ability to read small
print weakens as one ages beyond 40 years old. Non-
surgical solutions are reading glasses or contact lenses.
Surgical solutions include cornea-based treatments such
as laser vision correction or inlays while lens-based
solutions include multifocal or accommodating intraocu-
lar lenses implanted after removal of the natural lens.
Laser in-situ keratomileusis (LASIK) involves creating
a flap and reshaping the cornea to correct refractive
power and improve distance vision. LASIK is also being
used to correct presbyopia in a variety of ways. In con-
ventional monovision LASIK, the dominant eye is tar-
geted for Plano refraction for good distance vision while
the non-dominant eye is targeted to −1.50 D for good
near vision [1, 2]. More advanced laser algorithms have
been developed to produce a multifocal ablation or ma-
nipulate asphericity to improve near vision [3–9].
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Multifocal ablations can be categorized into “center-
distance” or “center-near” ablation profiles. The Pseudo
accommodative Cornea (PAC, Nidek, Aichi, Japan) cre-
ates an aspheric cornea that is flatter in the center to
provide good distance vision (Center-distance) and is
steeper away from the center forming a peripheral near
zone (concentric ring for near vision) [10]. The Supracor
(Bausch and Lomb Technolas, Munich, Germany) and
PresbyMax (Schwind, Kleinostheim, Germany) algorithms
create topographic profiles wherein there is an elevation
in the center of the cornea for good reading vision
(Center-near) and flatter topography towards the periph-
ery for good intermediate and distance vision [11, 12].
While presentations in congresses and publications re-
port good outcomes in terms of improved near vision, it
is difficult to compare the ablations directly with each
other because the algorithms are proprietary and specific
to a particular brand of laser equipment. In addition, the
laser treatment algorithms across different brands are at
different stages of product development. Therefore,
comparisons may not be equal if the algorithm is not in
its final commercial form.
Supracor creates a varifocal cornea wherein there is a 12
μm elevation in the central 3 mm of the cornea to give a
near addition of approximately two diopters (D). Outside
of the near addition is an aberration-optimized transition
zone that gives good intermediate and good distance
vision. The algorithm is available in the Technolas 217P
and Teneo 317 excimer lasers (Bausch and Lomb Techno-
las, Munich, Germany). Since Supracor is a LASIK-based
algorithm, its main advantage is it can correct refractive
error and presbyopia in a single procedure. In clinical
practice, Supracor can be used in one eye or in both eyes
depending on each patient’s needs and expectations.
The objective of our retrospective study is to evaluate
the safety and effectiveness of the SUPRACOR presbyopic
excimer laser treatment algorithm for hyperopic eyes, with
or without astigmatism. A secondary objective is to com-
pare the binocular visual outcomes of hyperopic patients
that underwent Supracor in one or both eyes.
Methods
This is a retrospective, single center, single surgeon, case
series of hyperopic presbyopic patients who underwent
presbyopic Supracor LASIK treatment. This study was per-
formed according to the tenets of the Declaration of
Helsinki and was approved by the ethics committee of our
institution. In Supracor-treated eyes, a 120 μm flap was cre-
ated using either the XP microkeratome (Bausch and Lomb
Technolas, Munich, Germany) or the Victus femtosecond
laser (Bausch and Lomb Technolas, Munich, Germany).
The Technolas 217P laser (Bausch and Lomb Technolas,
Munich, Germany) was used to perform excimer laser
treatment. The recommended refractive target for Supracor
was −0.50 D spherical equivalent (SE). The optical zone size
was 6 mm. Postoperative topical medication regimen con-
sisted of Levofloxacin (Oftaquix, Santen Pharmaceutical,
Osaka, Japan) four times a day, Prednisolone acetate 1%
(Pred forte, Allergan, California, USA) every hour for 2 days
then tapered to four times a day, and Ketorolac (Acular,
Allergan, California, USA) four times a day.
Outcomes
The data of all patients diagnosed with hyperopia
(Sphere ≥ +0.0 D) and presbyopia (reading add ≥ 1.0 D)
who underwent SUPRACOR presbyopic excimer laser
treatment on at least one eye for near indication from
May 2011 to May 2013 with a minimum follow-up of
1 month were retrospectively reviewed. The data of 69
Supracor-treated eyes from 58 patients were included in this
study. Excluded were the presence of ocular surface disease,
abnormal corneal topography, and less than 5.0 mm wetting
on Schirmer testing over 5 min without topical anesthesia.
Patient demographics, manifest refraction, eye domin-
ance, monocular and binocular distance, intermediate and
near visual acuity measurements were obtained on the pre-
operative, 1 week, 1 month, 3 months, and 6 months post-
operative follow-up. Corneal topography using the Orbscan
IIz (Bausch & Lomb, Munich, Germany), and undilated
and dilated wavefront aberrometry measurements using the
Zywave II (Bausch & Lomb, Munich, Germany) were like-
wise obtained for this study on the pre-operative, 1 month,
3 months, and 6 months post-operative follow-up.
Supracor treatment outcomes were analyzed based on
effectiveness: uncorrected distance visual acuity (UDVA),
uncorrected intermediate visual acuity (UIVA), uncor-
rected near visual acuity (UNVA), manifest refraction
spherical equivalent (MRSE), and safety (loss of lines of
best corrected distance visual acuity)–change in corneal
topography and change in the 6 mm higher order aber-
ration from preoperative to 6 month postoperative visit.
A sub-analysis of binocular visual outcomes was per-
formed after patients were subdivided into three groups:
Group A: bilateral Supracor; Group B: one eye Supracor,
fellow eye treated with hyperopic LASIK; Group C: one
eye Supracor, fellow eye untreated.
Statistical analysis
Data were encoded and tallied in Microsoft Excel 2007
and descriptive statistics were generated for all variables.
Visual acuity was expressed in the logarithm of minimum
angle of resolution (LogMAR) scale for the analysis. For
numerical data, mean and standard deviation were gener-
ated. One way Analysis of Variance, and paired two-tailed
T-test on samples were performed for the quantitative
data with the significance level set at p < 0.05.
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Results
From May 2011 to May 2013, 69 eyes of 58 hyperopic
patients, consisting of 25 males and 33 females, under-
went Supracor presbyopic laser treatment for near indi-
cation. The mean age was 51.6 years. Analysis of
patients was further subdivided to three treatment
groups: Group A (n = 11 patients) had bilateral Supracor
treatment; Group B (n = 18 patients) had Supracor on
one eye and Hyperopic LASIK on the fellow eye; and
Group C (n = 29 patients) underwent Supracor on one
eye and no treatment on the fellow eye (Table 1).
Supracor-treated eyes
Efficacy
Pre-operatively, the mean MRSE of all Supracor-treated
eyes was 1.37 ± 0.72 D, mean sphere was +1.57 ± 0.71 D
and mean astigmatism was −0.41 ± 0.39 D. At 6 months
postoperatively, the mean MRSE was −0.43 ± 0.59 D, the
mean sphere was −0.20 ± 0.57 D and the mean astigma-
tism was −0.47 ± 0.29 D (Table 2).
Pre-operatively, the mean monocular UDVA was log
MAR 0.35 (20/50), UIVA was 0.35 (20/50), and UNVA
was 0.61 (J9). At 6 months post operatively, the binocu-
lar cumulative UDVA (Fig. 1) was 20/20 or better in 63%
of patients and 20/25 or better in 85% of patients.
Figure 2 shows the uncorrected cumulative monocular
UDVA at 6 months wherein 54% of patients were 20/25
or better. For the uncorrected near visual acuity at
6 months post operatively, Fig. 3 shows the cumulative










Patients 11 18 29 n/a
Male 3 10 12 n/a
Female 8 8 17
Mean Age (Years) 53.18 ± 3.20 50.56 ± 4.38 50.83 ± 4.68 0.70
UDVA 0.63 ± 0.18 0.43 ± 0.21 0.05 ± 0.06 0.00
UIVA 0.40 ± 0.00 0.40 ± 0.00 0.30 ± 0.12 0.16
UNVA 0.70 ± 0.00 0.68 ± 0.06 0.53 ± 0.22 0.16
Sphere (D) 1.98 ± 0.39 1.97 ± 0.69 1.02 ± 0.52 0.00
Cylinder (D) −0.39 ± 0.26 −0.33 ± 0.33 −0.47 ± 0.49 0.46
Spherical Equivalent
(SE) (D)
1.78 ± 0.34 1.81 ± 0.72 0.78 ± 0.48 0.00
UDVA= uncorrected distance visual acuity; UIVA= uncorrected intermediate
visual acuity; UNVA= uncorrected near visual acuity
Table 2 Refractive Outcome
Time
(N = eyes)
Sphere (D) Cylinder (D) Spherical Equivalent
(MRSE) (D)
Mean St-Dev Mean St-Dev Mean St-Dev
Pre-Op (69) 1.57 0.71 −0.41 0.39 1.37 0.72
1 Week (62) −0.37 0.56 −0.58 0.32 −0.66 0.53
1 Month (64) −0.42 0.68 −0.64 0.36 −0.74 0.67
3 Months (45) −0.26 0.58 −0.59 0.29 −0.55 0.55
6 Months (38) −0.20 0.57 −0.47 0.29 −0.43 0.59
Fig. 1 Cumulative UCDVA Binocular Snellen Visual Acuity (20/x or better)
Fig. 2 Cumulative UCDVA Monocular Snellen Visual Acuity (20/x or better)
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Predictability
Figure 4 shows the intended SE refraction versus the
achieved SE refraction at 6 months postoperatively. Figure 5
shows the SE refractive accuracy while Fig. 6 shows the
postoperative refractive astigmatism amplitude.
Safety
At 6 months postoperatively, 6% lost two lines of
best-corrected distance visual acuity (BCDVA) and
12% lost one line among all Supracor eyes (Fig. 7).
Among the subdivided groups, 14% of the bilateral
Supracor eyes (Group A) lost two lines and 18% lost
one line of BCDVA (Fig. 8), 6% of Group B lost two
lines and 33% lost one line of BCDVA (Fig. 9), and
4% of Group C loss two lines and 14% lost one line
of BCDVA (Fig. 10). One eye developed an epithelial
ingrowth which was resolved after cleaning the flap
interface. One eye developed steroid-induced ocular
Fig. 3 Cumulative uncorrected near visual acuity
Fig. 4 Intended spherical equivalent (SE) refraction versus the
achieved SE refraction
Fig. 5 Spherical Equivalent Accuracy, Achieved vs. Target
Fig. 6 Refractive Astigmatism Amplitude
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hypertension which resolved after stopping prednisol-
one and instilling brimonidine plus timolol eye drops.
There were no intraoperative complications but four
patients eventually needed enhancement after
2 months (n = 1), 6 months (n = 1), 12 months (n = 1),
and 14 months (n = 1) follow up. No other complica-
tions were observed.
Binocular vision results
In Group A, the mean MRSE of the Supracor-treated
dominant eye was 1.81 ± 0.32 D preoperatively and
−0.47 ± 0.24 D at 6 months. The non-dominant
Supracor-treated eye had MRSE of 1.76 ± 0.38 D
preoperatively and −0.59 ± 0.64 D after 6 months. In
Group B, the mean MRSE of the dominant eye was 1.63
± 0.46 D preoperatively and 6 months after hyperopic
LASIK was 0.01 ± 0.21 D. The non-dominant Supracor-
treated eye had a mean MRSE of 1.81 ± 0.72 D and was
−0.55 ± 0.63 D 6 months after Supracor. In Group C, the
mean MRSE of the dominant eye left untreated was
0.76 ± 0.38 D preoperatively and remained at +0.60 ±




























































Loss 1Loss 2Loss 3 or
more
SUPRACOR Lost/Gained Lines







1 Month   (64)
3 Months (44) 
6 Months (33) 
Fig. 7 Gains/Loss of lines of all cases
Fig. 8 Gains/Loss of lines of Group A (Supracor + Supracor)
Fig. 9 Gains/Loss of lines of Group B (Supracor + LASIK)
Fig. 10 Gains/Loss of lines of Group C (Supracor + No treatment)
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mean MRSE of the non-dominant Supracor-treated eye
was 0.78 ± 0.48 D preoperatively and was −0.45 ± 0.38 D
6 months after Supracor (Table 3).
Six months after treatment, the mean binocular UDVA
of Group A (Table 4) was 0.02 ± 0.05 logMAR (20/20),
Group B was 0.00 ± 0.00 logMAR (20/20) and Group C
was 0.02 ± 0.05 logMAR (20/20). The mean binocular
UIVA of Group A (Table 5) was −0.10 ± 0.08 logMAR (20/
16), Group B was 0.00 ± 0.05 logMAR (20/20) and Group
C was −0.10 ± 0.17 logMAR (20/16). The mean binocular
UNVA of Group A (Table 6) was −0.07 ± 0.05 logMAR (J1
+), Group B was 0.00 ± 0.14 logMAR (J1) and Group C
was 0.00 ± 0.10 logMAR (J1). The mean binocular UDVA,
UIVA, UNVA for each treatment group remained stable
and showed no significant difference between groups
throughout the follow up period.
Corneal Topography
Corneal curvature tests were performed on all Supracor-
treated eyes using the Orbscan IIz Corneal Topography
(Bausch & Lomb, Munich, Germany). Comparing pre-
operative and 6 month postoperative measurements, a
mean 1.0 D corneal steeping at the central 3 mm and 0.7
D change at the central 5 mm were observed (Fig. 11).
Corneal curvature changes from preoperative to the
6 month postoperative visit were compared between
Supracor-treated eyes and hyperopic LASIK-treated eyes
in Group B patients (Fig. 12). Mean steepening at 3 mm
was similar between treatments while the degree of
steepening at 5 mm was observed more in the Supracor-
treated eyes (Fig. 13).
Higher order aberrations
Higher order aberrations were measured using the Zywave
II wavefront Aberrometry (Bausch & Lomb, Munich,
Germany). Vertical coma increased from −0.02 μm
preoperatively to +0.10 μm at 6 months after Supracor
(p = 0.04). Quadrafoil increased from −0.01 μm pre-
operatively to +0.03 μm at 6 months (p = 0.03). Fourth
order spherical aberration changed from +0.20 μm
preoperatively to −0.14 μm at 6 months postoperatively
(p < 0.0001). Horizontal coma, vertical trefoil, and
horizontal trefoil did not change significantly (Fig. 14).
The change in higher order aberrations was compared
between Supracor-treated and hyperopic LASIK-treated
eyes in Group B patients. The increase in negative 4thor-
der spherical aberration (p = 0.03) was higher in the
Supracor-treated eyes compared to eyes that underwent
hyperopic Lasik. No significant difference was seen on
vertical trefoil, horizontal trefoil, vertical coma, horizon-
tal coma, and quadrafoil (Fig. 15).
Retreatments
Out of the 69 hyperopic eyes that had Supracor, four
eyes underwent retreatment (5.7%). The indications for
retreatment were decreased UNVA and a regression
towards hyperopia of the refractive spherical equivalent
of their post-Supracor eyes. A non-wavefront standard
LASIK algorithm was used with a target of −0.50 D. We
noted an improvement in the UNVA for all of the
patients post-enhancement. Their post-enhancement
results are shown below (Table 7).
Discussion
Surgical correction for presbyopia remains one of the
most challenging aspects of refractive surgery. Several
LASIK-based strategies have been or are being
developed to address this gap. Our retrospective study
presents our early experience and outcomes with the
Supracor algorithm (Bausch and Lomb Technolas,



















Pre-Op 1.81 ± 0.32 1.76 ± 0.38 1.63 ± 0.46 1.81 ± 0.72 0.76 ± 0.38 0.78 ± 0.48
1 month −0.39 ± 0.55 −0.51 ± 0.61 −0.16 ± 0.37 −1.06 ± 0.78 0.68 ± 0.44 −0.78 ± 0.59
3 months −0.32 ± 0.40 −0.53 ± 0.42 0.10 ± 0.31 −0.76 ± 0.63 0.66 ± 0.39 −0.51 ± 0.60
6 months −0.47 ± 0.24 −0.59 ± 0.64 0.01 ± 0.21 −0.55 ± 0.63 0.60 ± 0.46 −0.45 ± 0.38











Pre OP 0.63 ± 0.18 (20/80) 0.43 ± 0.21 (20/50) 0.04 ± 0.06 (20/20) 0.00
1 Month 0.09 ± 0.10 (20/25) 0.03 ± 0.05 (20/20) 0.04 ± 0.05 (20/20) 0.12
3 Months 0.01 ± 0.00 (20/20) 0.03 ± 0.06 (20/20) 0.07 ± 0.06 (20/20) 0.15
6 Months 0.02 ± 0.05 (20/20) 0.00 ± 0.00 (20/20) 0.02 ± 0.05 (20/20) 0.36
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Munich, Germany) on hyperopic presbyopic patients. In
addition to reporting the efficacy and safety of the algo-
rithm, we analyzed the refractive and binocular visual
outcomes of three subgroups of patients–bilateral
Supracor (Group A), one eye Supracor with fellow eye
hyperopic LASIK (Group B) and one eye Supracor with
fellow eye untreated (Group C).
The Supracor algorithm creates an elevation 12 μm
high and 3 mm in diameter in the central cornea along
the visual axis. The elevation is surrounded by an
aspheric optimized area where a smooth transition
creates the intermediate vision zone while the distance
vision zone is positioned in the periphery (Fig. 16). This
varifocal principle allows simultaneous good distance,
intermediate and near vision. Supracor makes use of the
central-near, peripheral-distance concept wherein during
natural accommodation when the eye focuses on near
objects, the pupil constricts and the eye looks thru the
near-add elevation. When the eye is looking at a
distance, the pupil dilates and allows the peripheral rays
to pass through the aspheric optimized periphery to
improve distance vision. Supracor provides approxi-
mately two dioptres of near vision. With the refractive
target of −0.50 D spherical equivalent, it is believed that
this −0.50 D [13] residual refractive error does not
significantly sacrifice distance vision but adds to the 2.0
D near add, thereby increasing the ability to read small
print with a total add power of 2.5 D.
In our study, the Supracor LASIK treatment was able
to achieve a mean spherical equivalent of −0.43 ± 0.59 D
at the 6 month follow up (Table 2). This resulted in an
85% uncorrected distance vision of 20/25 (Fig. 1), and
93% near vision of J2 (Fig. 3). A noticeable trend was
that the eyes were initially more myopic but settled near
the target refraction over time. This refractive trend mir-
rors the visual recovery wherein distance vision was ini-
tially unclear but improved over time while the near and
intermediate vision was good from the start.
Safety is a significant concern for new treatments. In
our study, 7% lost two or more lines of BCDVA at
6 month post-operative period. We attribute the lost
lines primarily to dry eye, which affects older presbyopic
patients and is aggravated by the LASIK procedure itself.
Therefore, we placed punctual plugs and start patients
on cyclosporine (Restasis, Allergan, USA). Another pos-
sible reason for lost lines of vision is the induced higher
order aberrations. Similar and even greater losses of
BCDVA have been reported in various cornea-based
presbyopia treatments. Alió et al. [4] reported a loss of a
maximum of two lines of BCDVA in 28% of cases in
their study of central presbyopic LASIK in hyperopic
patients. A study by Ryan et al. [13] showed a similar
rate of loss of two or more lines of monocular BCDVA
at 6.5%. Using the biaspheric ablation profile of Presby-
Max (Schwind, Kleinostheim, Germany), Uthoff et al.
[14] found that 15% lost two lines or more of BCDVA
monocularly and 13% binocularly at 6 months in the
treatment of presbyopic hyperopic, emmetropic, and
myopic patients while Cosar and Sener [15] reported a











Pre OP 0.40 ± 0.00 (20/50) 0.40 ± 0.00 (20/50) 0.30 ± 0.11 (20/40) 0.00
1 Month −0.02 ± 0.09 (20/20) −0.01 ± 0.07 (20/20) 0.05 ± 0.06 (20/20) 0.053
3 Months −0.05 ± 0.07 (20/20) 0.04 ± 0.10 (20/20) 0.00 ± 0.11 (20/20) 0.13
6 Months −0.10 ± 0.08 (20/16) 0.00 ± 0.05 (20/20) −0.10 ± 0.17 (20/16) 0.19
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Fig. 11 Post-operative corneal steepening
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loss of 28% in one line and 10% loss of two lines of
BCDVA at 6 months.
Ryan and Keefe [13] reported that Supracor provided a
high level of spectacle independence for near vision, but
around 22% had unsatisfactory uncorrected distance
vision that required retreatment. In our case series, 5.7%
of eyes eventually needed retreatment. However, unlike
the Ryan and Keefe study wherein the main indication
for retreatment was poor uncorrected distance vision,
our indication for all four enhancements was deterior-
ation of uncorrected near vision.
We had three subgroups of patients who underwent
Supracor because we customized our treatment recom-
mendations based on individualized vision conditions.
Hyperopic patients seeking presbyopia treatment can
have minimal hyperopia wherein distance vision is good
even without glasses or visually significant hyperopia
wherein distance vision is poor without eyeglasses.
Checking eye dominance is paramount during the
screening process because the non-dominant eye gets a
Supracor treatment. For patients with uncorrected
distance vision of 20/30 or better in the dominant eye,
we would suggest Supracor treatment only in the non-
dominant eye and no treatment in the fellow eye. If the
dominant eye has an uncorrected distance vision worse
than 20/30, we give the patient the option of hyperopic
LASIK in the dominant eye if they need to ensure good
far vision or Supracor LASIK in the dominant eye if they
prefer good near vision with the understanding that
there is a mild sacrifice in distance vision. Our results
support this treatment differentiation because the mean
uncorrected distance vision of Supracor-treated eyes is
20/25 and not 20/20 which is the typical outcome in
hyperopic LASIK-treated eyes. In addition, because of
the initial overly myopic outcomes, improvement in
distance vision takes time so it is important to set the
proper expectations if patients decide on bilateral Supra-
cor Lasik. Analyzing the three subgroups yielded
similarly good uncorrected distance, intermediate and















Pre-OP (18) 1 Month (17) 3 Months (13) 6 Months (8)
3 mm
5 mm
Central Corneal Steepness 























Pre-OP (18) 1 Month (17) 3 Months (14) 6 Months (8)
3 mm
5 mm
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High Order Aberrations 
(All Supracor Eyes)
p= 0.34         0.04 0.46               0.38                0.03 0.00































Pre-OP   (58) 
1 Month   (52)
3 Months (37) 
6 Months (32) 
Vertical Vertical        Coma Horizontal       Quadrafoil Spherical 
Trefoil                      Coma              Trefoil Aberration 
Fig. 14 Higher order aberrations of all Supracor treated eyes
Fig. 15 Higher order aberrations of Group B
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differences between monolateral and bilateral Supracor
are minimal but more importantly, these outcomes
confirm that Supracor LASIK is a viable option for
presbyopia treatment.
Corneal steepening occurs after hyperopic LASIK but to
a greater magnitude after Supracor treatments (Figs 11
and 12). Vertical coma, quadrafoil, and negative spherical
aberration were shown to have significantly increased after
Supracor. This was consistent with previous studies
reporting that LASIK increases higher order wavefront ab-
errations of the cornea, dependent on the amount of re-
fractive correction; [16] and that hyperopic LASIK
induced negative spherical aberrations and more third-
and fifth-order coma-like aberrations than myopic
LASIK [17]. Taken together, the mechanism of action of
Supracor can be better understood. The central eleva-
tion and aspheric optimized mid periphery created by
the Supracor procedure is manifested as central corneal
steepening and a negative spherical aberration that are
believed to improve depth of focus. Coupled with a
−0.50 D refractive outcome, presbyopia treatment is
enhanced.
Table 7 Post-Enhancement Visual and Refractive Outcomes
Pre Supracor Patient A Patient B Patient C Patient D
UDVA 20/20 20/30 20/60 20/25
UIVA 20/32 20/50 20/50 20/25
UNVA J5 J10 J10 J10
Sphere (D) +0.50 +1.25 +1.75 +0.50
Cylinder (D) −0.25 −0.50 −0.75 −0.75
Spherical Equivalent (D) +0.375 +1.00 +1.375 +0.125
Pre Enhancement 14 months 6 months 1 year 2 months
UDVA 20/20 20/25 20/20 20/25
UIVA 20/25 20/16 20/40 20/25
UNVA J3 J1 (doubling) J10 J5
Sphere (D) Plano Plano +0.50 +0.50
Cylinder (D) −0.25 −0.50 0.00 −0.25
Spherical Equivalent (D) −0.125 −0.25 +0.50 +0.375
Latest follow up 2.5 years 1 year 3 weeks 6 months
UDVA 20/20 20/30 20/50 20/30
UIVA 20/25 20/25 20/30 20/25
UNVA J1 J1 J2 J1
Sphere (D) −0.25 −1.00 −0.50 −0.50
Cylinder (D) −0.25 −0.50 −0.25 −1.00
Spherical Equivalent (D) −0.325 −1.25 −0.63 −1.00
UDVA= uncorrected distance visual acuity; UIVA= uncorrected intermediate
visual acuity; UNVA= uncorrected near visual acuity
Fig. 16 Post-Operative Zywave Aberration Sample Image
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Conclusions
In conclusion, our study has shown that the Supracor al-
gorithm is safe and effective for hyperopic patients in
correcting refractive error and presbyopia simultan-
eously in a single LASIK treatment. Supracor can be
used in one or both eyes depending on patient needs
and expectations. Though treatment modalities in each
subgroup translated to significantly good outcomes, we
advocate a conservative approach of monolateral Supra-
cor treatment to ensure good distance vision while im-
proving near vision in a modified mini-monovision
approach. Enhancements can be performed to further
improve distance or near vision outcomes depending on
patients' needs or occurrence of regression. The limita-
tions of our study are that monolateral or bilateral treat-
ments were not randomly assigned in a prospective
manner, the study population is quite small, question-
naires on patient satisfaction and spectacle independ-
ence were not provided to patients for analysis, and
quality of vision tests were performed. As a clinician,
we recommend careful patient selection, managing, ex-
pectations and critical decision-making to increase the
satisfaction rate of patients seeking any form of presby-
opia LASIK treatment such as Supracor.
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